News | March 17, 2021
LifeClean and Lonza Specialty Ingredients sign distribution agreement for disinfectants
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
174 applications were received for 23 eligible products under Target Segment IV - Other Chemical Synthesis Based KSMs/ Drug Intermediates/APIs.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
Candid Powder brand is a market-leader in its category, with a market share of 64% in the medicated powder category.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Tiger can no longer make an important biotin intermediate using a DSM patented process.
PEL will explore the PLI scheme and apply if its beneficial.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Subscribe To Our Newsletter & Stay Updated
